1
|
Visintin A, Knowlton K, Tyminski E, Lin CI, Zheng X, Marquette K, Jain S, Tchistiakova L, Li D, O'Donnell CJ, Maderna A, Cao X, Dunn R, Snyder WB, Abraham AK, Leal M, Shetty S, Barry A, Zawel L, Coyle AJ, Dvorak HF, Jaminet SC. Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature. Mol Cancer Ther 2015; 14:1868-76. [PMID: 26089370 DOI: 10.1158/1535-7163.mct-15-0188] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Accepted: 06/07/2015] [Indexed: 11/16/2022]
Abstract
Antibody-drug conjugates (ADC) represent a promising therapeutic modality for managing cancer. Here, we report a novel humanized ADC that targets the tetraspanin-like protein TM4SF1. TM4SF1 is highly expressed on the plasma membranes of many human cancer cells and also on the endothelial cells lining tumor blood vessels. TM4SF1 is internalized upon interaction with antibodies. We hypothesized that an ADC against TM4SF1 would inhibit cancer growth directly by killing cancer cells and indirectly by attacking the tumor vasculature. We generated a humanized anti-human TM4SF1 monoclonal antibody, v1.10, and armed it with an auristatin cytotoxic agent LP2 (chemical name mc-3377). v1.10-LP2 selectively killed cultured human tumor cell lines and human endothelial cells that express TM4SF1. Acting as a single agent, v1.10-LP2 induced complete regression of several TM4SF1-expressing tumor xenografts in nude mice, including non-small cell lung cancer and pancreas, prostate, and colon cancers. As v1.10 did not react with mouse TM4SF1, it could not target the mouse tumor vasculature. Therefore, we generated a surrogate anti-mouse TM4SF1 antibody, 2A7A, and conjugated it to LP2. At 3 mpk, 2A7A-LP2 regressed several tumor xenografts without noticeable toxicity. Combination therapy with v1.10-LP2 and 2A7A-LP2 together was more effective than either ADC alone. These data provide proof-of-concept that TM4SF1-targeting ADCs have potential as anticancer agents with dual action against tumor cells and the tumor vasculature. Such agents could offer exceptional therapeutic value and warrant further investigation. Mol Cancer Ther; 14(8); 1868-76. ©2015 AACR.
Collapse
Affiliation(s)
- Alberto Visintin
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts
| | - Kelly Knowlton
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts
| | - Edyta Tyminski
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts
| | - Chi-Iou Lin
- The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts
| | - Xiang Zheng
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts
| | - Kimberly Marquette
- Pfizer Inc., Global Biotherapeutic Technologies (GBT), Cambridge, Massachusetts
| | - Sadhana Jain
- Pfizer Inc., Global Biotherapeutic Technologies (GBT), Cambridge, Massachusetts
| | | | - Dan Li
- The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts
| | | | - Andreas Maderna
- Pfizer Inc., Worldwide Medicinal Chemistry, Groton, Connecticut
| | - Xianjun Cao
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), San Diego, California
| | - Robert Dunn
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), San Diego, California
| | - William B Snyder
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), San Diego, California
| | - Anson K Abraham
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts
| | - Mauricio Leal
- Pfizer Inc., Pharmacokinetics, Dynamics and Metabolism (PDM), Pearl River, New York
| | - Shoba Shetty
- Pfizer Inc., Drug Safety R&D, Investigative Toxicology, Groton, Connecticut
| | - Anthony Barry
- Pfizer Inc., Biotherapeutics Pharmaceutical Sciences, Andover, Massachusetts
| | - Leigh Zawel
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts
| | - Anthony J Coyle
- Pfizer Inc., Centers for Therapeutic Innovation (CTI), Boston, Massachusetts
| | - Harold F Dvorak
- The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts.
| | - Shou-Ching Jaminet
- The Center for Vascular Biology Research and the Departments of Pathology, Beth Israel Deaconess Medical Center (BIDMC) and Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
2
|
Kohane IS, Szolovits P. Marco Ramoni: an appreciation of academic achievement. J Am Med Inform Assoc 2011; 18:367-9. [PMID: 21474623 PMCID: PMC3128413 DOI: 10.1136/amiajnl-2011-000218] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2011] [Accepted: 03/22/2011] [Indexed: 01/28/2023] Open
Abstract
We review the scholarly career of our colleague, Marco Ramoni, who died unexpectedly in the summer of 2010. His work mainly explored the development and application of Bayesian techniques to model clinical, public health, and bioinformatics questions. His contributions have led to improvements in our ability to model behavior that evolves in time, to explore systematic relationships among large sets of covariates, and to tease out the meaning of data on the role of genetic variation in the genesis of important diseases.
Collapse
Affiliation(s)
- Isaac S Kohane
- Harvard Medical School, Children's Hospital Informatics Program, Boston, Massachusetts, USA
| | - Peter Szolovits
- MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, Massachusetts, USA
| |
Collapse
|